Literature DB >> 17543304

Babesia gibsoni: detection during experimental infections and after combined atovaquone and azithromycin therapy.

R Jefferies1, U M Ryan, J Jardine, I D Robertson, P J Irwin.   

Abstract

Babesia gibsoni is a protozoan parasite of dogs worldwide yet both an effective treatment and a reliable method for detecting subclinical cases of this emerging infection remain elusive. Experimental B. gibsoni infections were established in vivo to investigate the efficacy of combined atovaquone and azithromycin drug therapy and to determine the detection limits of a nested-PCR, IFAT and microscopy during various stages of infection. While atovaquone and azithromycin produced a reduction in parasitaemia, it did not eliminate the parasite and drug resistance appeared to develop in one dog. Polymerase chain reaction was found to be most useful in detecting infection in the pre-acute and acute stages, while IFAT was most reliable during chronic infections. Microscopy is suggested to be only effective for detecting acute stage infections. This study also describes the detection of B. gibsoni in tissue samples during chronic infections for the first time, suggesting possible sequestration of this parasite.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17543304     DOI: 10.1016/j.exppara.2007.03.016

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  10 in total

Review 1.  A review of canine babesiosis: the European perspective.

Authors:  Laia Solano-Gallego; Ángel Sainz; Xavier Roura; Agustín Estrada-Peña; Guadalupe Miró
Journal:  Parasit Vectors       Date:  2016-06-11       Impact factor: 3.876

Review 2.  A review of piroplasmid infections in wild carnivores worldwide: importance for domestic animal health and wildlife conservation.

Authors:  Mario Alvarado-Rybak; Laia Solano-Gallego; Javier Millán
Journal:  Parasit Vectors       Date:  2016-10-10       Impact factor: 3.876

3.  Efficacy of Azithromycin and Compounded Atovaquone for Treatment of Babesia gibsoni in Dogs.

Authors:  S K Kirk; J K Levy; P C Crawford
Journal:  J Vet Intern Med       Date:  2017-06-17       Impact factor: 3.333

4.  Prevalence of Vector-Borne Pathogens in Southern California Dogs With Clinical and Laboratory Abnormalities Consistent With Immune-Mediated Disease.

Authors:  L Kidd; B Qurollo; M Lappin; K Richter; J R Hart; S Hill; C Osmond; E B Breitschwerdt
Journal:  J Vet Intern Med       Date:  2017-05-30       Impact factor: 3.333

5.  Protective efficacy of Babesia gibsoni culture-derived exoantigens against the challenge infection in dogs.

Authors:  Fujiko Sunaga; Sachiko Arai; Seigo Itoh; Satoshi Taharaguchi
Journal:  Parasitol Res       Date:  2014-02-18       Impact factor: 2.383

6.  Canine babesiosis: from molecular taxonomy to control.

Authors:  Peter J Irwin
Journal:  Parasit Vectors       Date:  2009-03-26       Impact factor: 3.876

Review 7.  New Molecules in Babesia gibsoni and their application for diagnosis, vaccine development, and drug discovery.

Authors:  Youn-Kyoung Goo; Xuenan Xuan
Journal:  Korean J Parasitol       Date:  2014-08-29       Impact factor: 1.341

8.  Babesia gibsoni cytochrome b mutations in canine blood samples submitted to a US veterinary diagnostic laboratory.

Authors:  Adam J Birkenheuer; Henry S Marr; James M Wilson; Edward B Breitschwerdt; Barbara A Qurollo
Journal:  J Vet Intern Med       Date:  2018-10-11       Impact factor: 3.333

9.  An alternative combination therapy with metronidazole, clindamycin and doxycycline for Babesia gibsoni (Asian genotype) in dogs in Hong Kong.

Authors:  Angel Almendros; Richard Burchell; Janelle Wierenga
Journal:  J Vet Med Sci       Date:  2020-08-04       Impact factor: 1.267

Review 10.  The Etiology, Incidence, Pathogenesis, Diagnostics, and Treatment of Canine Babesiosis Caused by Babesia gibsoni Infection.

Authors:  Martina Karasová; Csilla Tóthová; Simona Grelová; Mária Fialkovičová
Journal:  Animals (Basel)       Date:  2022-03-16       Impact factor: 2.752

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.